Related Experiment Videos
Placebo-controlled immunotherapy with Cocos nucifera pollen extract
P R Karmakar1, A Das, B P Chatterjee
1Department of Biological Chemistry, Indian Association for the Cultivation of Science, Jadavpur, Calcutta.
International Archives of Allergy and Immunology
|January 1, 1994
Summary
Cocos nucifera pollen extract immunotherapy (CPE-IT) significantly improved allergy symptoms and modified immune responses in patients with C. nucifera pollen allergy compared to placebo. This immunotherapy offers a promising therapeutic option for managing pollen allergies.
Area of Science:
- Allergy and Immunology
- Immunotherapy Research
- Clinical Trials
Background:
- Cocos nucifera pollen is a known allergen.
- Allergic rhinitis affects a significant portion of the population.
- Effective immunotherapies are needed for pollen allergies.
Purpose of the Study:
- To evaluate the clinical effectiveness of Cocos nucifera pollen extract immunotherapy (CPE-IT).
- To assess the serological changes associated with CPE-IT in allergic patients.
Main Methods:
- A randomized, placebo-controlled study involving 96 patients allergic to C. nucifera pollen.
- Clinical status assessed using symptom-medication scores over 6-12 months.
- Serological analysis of specific IgE and IgG levels before and after treatment.
Main Results:
- CPE-IT significantly improved clinical symptoms (p < 0.005) compared to placebo.
- Significant reduction in specific IgE (p < 0.001) and elevation in specific IgG (p < 0.01) observed post-CPE-IT.
- No significant correlation found between symptom improvement and serological changes.
Conclusions:
- CPE-IT demonstrates significant clinical efficacy in treating C. nucifera pollen allergy.
- The immunotherapy induces favorable changes in immunoglobulin levels.
- Further research may explore the mechanisms linking clinical outcomes and serological markers.